Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.

Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC Jr, Fleg JL, Rosenberg Y, Byington RP; ACCORDION Study Investigators.

JAMA Cardiol. 2017 Apr 1;2(4):370-380. doi: 10.1001/jamacardio.2016.4828.

2.

Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial.

Soliman EZ, Byington RP, Bigger JT, Evans G, Okin PM, Goff DC Jr, Chen H.

Hypertension. 2015 Dec;66(6):1123-9. doi: 10.1161/HYPERTENSIONAHA.115.06236. Epub 2015 Oct 12.

3.

Fibroblast growth factor 23 and incident CKD in type 2 diabetes.

Isakova T, Craven TE, Lee J, Scialla JJ, Xie H, Wahl P, Marcovina SM, Byington RP, Wolf M.

Clin J Am Soc Nephrol. 2015 Jan 7;10(1):29-38. doi: 10.2215/CJN.06190614. Epub 2014 Oct 24.

4.

Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.

Linz PE, Lovato LC, Byington RP, O'Connor PJ, Leiter LA, Weiss D, Force RW, Crouse JR, Ismail-Beigi F, Simmons DL, Papademetriou V, Ginsberg HN, Elam MB.

Diabetes Care. 2014;37(3):686-93. doi: 10.2337/dc13-0790. Epub 2013 Dec 2.

5.

Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial.

Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, Ambrosius WT, Lovato L, Applegate WB; ACCORD Investigators.

Diabetes Care. 2014;37(3):634-43. doi: 10.2337/dc13-1545. Epub 2013 Oct 29.

6.

Long-term effects of intensive glucose lowering on cardiovascular outcomes.

ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT.

N Engl J Med. 2011 Mar 3;364(9):818-28. doi: 10.1056/NEJMoa1006524.

7.

Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.

Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC Jr, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER; Action to Control Cardiovascular Risk in Diabetes Investigators.

Diabetes Care. 2010 May;33(5):983-90. doi: 10.2337/dc09-1278.

8.

Effects of combination lipid therapy in type 2 diabetes mellitus.

ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP.

N Engl J Med. 2010 Apr 29;362(17):1563-74. doi: 10.1056/NEJMoa1001282. Epub 2010 Mar 14. Erratum in: N Engl J Med. 2010 May 6;362(18):1748.

9.

Effects of intensive blood-pressure control in type 2 diabetes mellitus.

ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F.

N Engl J Med. 2010 Apr 29;362(17):1575-85. doi: 10.1056/NEJMoa1001286. Epub 2010 Mar 14.

10.

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.

Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME.

BMJ. 2010 Jan 8;340:b4909. doi: 10.1136/bmj.b4909.

11.

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M.

Diabetologia. 2009 Nov;52(11):2288-98. doi: 10.1007/s00125-009-1470-0. Epub 2009 Aug 5. Erratum in: Diabetologia. 2009 Nov;52(1):2470. Control Group [added].

PMID:
19655124
12.

Effects of intensive glucose lowering in type 2 diabetes.

Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT.

N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.

13.

Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG; ACCORD Study Group.

Am J Cardiol. 2007 Jun 18;99(12A):4i-20i. Epub 2007 Apr 12. Review.

PMID:
17599424
14.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD.

Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. Epub 2007 Apr 16.

PMID:
17599422
15.

The burden of treatment failure in type 2 diabetes: response to Brown et al.

Simons-Morton DG, Genuth S, Byington RP, Gerstein HC, Friedewald WT.

Diabetes Care. 2005 Mar;28(3):761-2. No abstract available.

PMID:
15735233
16.

Lessons learned from the prospective pravastatin pooling project.

Byington RP, Sacks FM.

Curr Atheroscler Rep. 2004 Sep;6(5):366-74. Review.

PMID:
15296703
17.

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.

Hennekens CH, Sacks FM, Tonkin A, Jukema JW, Byington RP, Pitt B, Berry DA, Berry SM, Ford NF, Walker AJ, Natarajan K, Sheng-Lin C, Fiedorek FT, Belder R.

Arch Intern Med. 2004 Jan 12;164(1):40-4.

PMID:
14718320
18.

Pregnancy-related death and health care services.

Harper MA, Byington RP, Espeland MA, Naughton M, Meyer R, Lane K.

Obstet Gynecol. 2003 Aug;102(2):273-8.

PMID:
12907099
19.

Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy.

Byington RP, Furberg CD, Herrington DM, Herd JA, Hunninghake D, Lowery M, Riley W, Craven T, Chaput L, Ireland CC, Applegate WB; Heart and Estrogen/Progestin Replacement Study Research Group.

Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1692-7.

PMID:
12377751
20.

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project.

Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, Davis BR, Friedman CP, Braunwald E.

Circulation. 2002 May 21;105(20):2341-6.

PMID:
12021218
21.

Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project.

Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, Shepherd J.

Circulation. 2001 Jan 23;103(3):387-92.

PMID:
11157690
22.

Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators.

Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W.

Circulation. 2000 Sep 26;102(13):1503-10.

PMID:
11004140
23.

Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.

Byington RP, Evans GW, Espeland MA, Applegate WB, Hunninghake DB, Probstfield J, Furberg CD.

Circulation. 1999 Jul 20;100(3):e14-7.

PMID:
10411862
24.

Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events.

Byington RP, Craven TE, Furberg CD, Pahor M.

Lancet. 1997 Oct 11;350(9084):1075-6. No abstract available.

PMID:
10213554
25.

Isradipine in prediabetic hypertensive subjects.

Byington RP, Furberg CD, Craven TE, Pahor M, Sowers JR.

Diabetes Care. 1998 Dec;21(12):2103-10.

PMID:
9839101
26.

HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data.

Crouse JR 3rd, Byington RP, Furberg CD.

Atherosclerosis. 1998 May;138(1):11-24. Review. Erratum in: Atherosclerosis 1998 Sep;140(1):193-4.

PMID:
9678767
27.

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F.

Diabetes Care. 1998 Apr;21(4):597-603.

PMID:
9571349
28.

Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).

Byington RP, Miller ME, Herrington D, Riley W, Pitt B, Furberg CD, Hunninghake DB, Mancini GB.

Am J Cardiol. 1997 Oct 15;80(8):1087-90.

PMID:
9352986
29.

Reductase inhibitor monotherapy and stroke prevention.

Crouse JR 3rd, Byington RP, Hoen HM, Furberg CD.

Arch Intern Med. 1997 Jun 23;157(12):1305-10.

PMID:
9201004
30.

The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)

Applegate WB, Furberg CD, Byington RP, Grimm R Jr.

JAMA. 1997 Jan 22-29;277(4):297; author reply 297-8. No abstract available.

PMID:
9002488
31.

[Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program].

Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB.

Fortschr Med. 1996 Mar 20;114(8):91-8. German.

PMID:
8647574
32.

Maximizing recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol.

Dolecek TA, Bradham KH, Espeland MA, Margitic SE, Byington RP, Hoen H, Kappelle LJ.

Control Clin Trials. 1996 Feb;17(1):33-45.

PMID:
8721800
33.

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.

Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB.

Circulation. 1995 Nov 1;92(9):2419-25.

PMID:
7586340
34.
35.

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II).

Byington RP, Furberg CD, Crouse JR 3rd, Espeland MA, Bond MG.

Am J Cardiol. 1995 Sep 28;76(9):54C-59C.

PMID:
7572688
36.

Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study.

Probstfield JL, Margitic SE, Byington RP, Espeland MA, Furberg CD.

Am J Cardiol. 1995 Sep 28;76(9):47C-53C.

PMID:
7572686
37.

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

Crouse JR 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD.

Am J Cardiol. 1995 Mar 1;75(7):455-9. Erratum in: Am J Cardiol 1995 Apr 15;75(12):862.

PMID:
7863988
38.

Reversing risk in coronary disease.

Byington RP, Furberg CD.

Lancet. 1995 Feb 4;345(8945):330. No abstract available.

PMID:
7837897
39.

Lessons learned from clinical trials with ultrasound end-points.

Furberg CD, Byington RP, Craven TE.

J Intern Med. 1994 Nov;236(5):575-80. Review. No abstract available.

PMID:
7964436
40.

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.

Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, et al.

Circulation. 1994 Oct;90(4):1679-87.

PMID:
7734010
41.

Pravastatin, lipids, and major coronary events.

Furberg CD, Byington RP, Crouse JR, Espeland MA.

Am J Cardiol. 1994 Jun 1;73(15):1133-4. No abstract available.

PMID:
8198043
42.

Calcium antagonists and atherosclerosis. The Multicenter Isradipine/Diuretic Atherosclerosis Study.

Furberg CD, Borhani NO, Byington RP, Gibbons ME, Sowers JR.

Am J Hypertens. 1993 Mar;6(3 Pt 2):24S-29S.

PMID:
8466723
43.

Methodological issues facing studies of atherosclerotic change.

Probstfield JL, Byington RP, Egan DA, Espeland MA, Margitic SE, Riley WA Jr, Furberg CD.

Circulation. 1993 Mar;87(3 Suppl):II74-81. Review.

PMID:
8443927
44.

Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome.

Crouse JR, Byington RP, Bond MG, Espeland MA, Sprinkle JW, McGovern M, Furberg CD.

Control Clin Trials. 1992 Dec;13(6):495-506.

PMID:
1334821
45.

Analysis strategies for serial multivariate ultrasonographic data that are incomplete.

Espeland MA, Byington RP, Hire D, Davis VG, Hartwell T, Probstfield J.

Stat Med. 1992 Jun 15;11(8):1041-56.

PMID:
1496192
46.

MIDAS, the Multicenter Isradipine/Diuretic Atherosclerosis Study. Design features and baseline data.

Applegate WB, Byington RP.

Am J Hypertens. 1991 Feb;4(2 Pt 2):114S-117S.

PMID:
1827000
47.
48.

Long term propranolol treatment and changes in body weight after myocardial infarction.

Rössner S, Taylor CL, Byington RP, Furberg CD.

BMJ. 1990 Apr 7;300(6729):902-3.

49.
50.

Multicenter study with isradipine and diuretics against atherosclerosis. US MIDAS Research Group.

Borhani NO, Brugger SB, Byington RP.

J Cardiovasc Pharmacol. 1990;15 Suppl 1:S23-9.

PMID:
1695298

Supplemental Content

Loading ...
Support Center